Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 6654 |
| PDBID: | 3P9W |
| Chains: | H_G |
| Organism: | Homo sapiens |
| Method: | XRD |
| Resolution (Å): | 2.41 |
| Reference: | 10.1016/j.jmb.2013.03.020 |
| Antibody | |
| Antibody: | V1a VHH |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | Vascular endothelial growth factor A (VEGF) |
| Antigen mutation: | No |
| Durg Target: | P15692 |
Sequence information
Antibody
Chain: H
Mutation: NULL
| >3P9W_H|Chain B, D, F, H|human VEGF|Homo sapiens (9606) EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIGWVRRAPGKGEELVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCYYHYYGWHPGYGLSYSSGQGTLVTVSS |
Antigen
Chain: G
Mutation: NULL
| >3P9W_G|Chain A, C, E, G|Vascular endothelial growth factor A|Homo sapiens (9606) GSQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDRAR |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| H: TYR33 VAL37 LYS43 GLY44 GLU45 GLU46 LEU47 ARG50 ASN54 TYR56 ARG58 TYR59 ALA60 ASP61 SER62 TYR93 HIS95 TYR97 GLY98 TRP99 SER100 TYR101 G: GLU38 TYR39 PRO40 ASP41 PHE47 VAL69 PRO70 THR71 GLU72 GLU73 SER74 ASN75 THR77 GLN79 ILE80 ARG82 HIS90 ILE91 GLY92 GLU93 MET94 SER95 LEU97 ASN100 ARG105 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
